Back to School: How biopharma can reboot drug development. Access exclusive analysis here

STX209: Phase IIb data

The double-blind, U.S. Phase IIb Study 209AS208 in 150 patients ages 5 to 21 years with ASD showed that oral STX209 for 12 weeks missed the primary endpoint of reducing patient-rated ABC-LSW subscale scores

Read the full 341 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE